Roche has announced that it will invest around $430 million Swiss francs ($387 million) in biotech drug research in its production sites Switzerland and Germany.

Around 280 million Swiss francs will be invested in expanding biotech drug research and development activities at Penzberg. This decision will ensure that the company's own value added chain is exploited to its full potential in the development and production of biopharmaceuticals mainly for oncology applications.

Source: Roche